Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon Provenge misses endpoint

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Dendreon's therapeutic prostate cancer vaccine Provenge did not reach statistical significance for the primary endpoint of a Phase III trial, the firm announces Jan. 11. "Final analysis of the primary endpoint, time to disease progression, in [study] D9902A did not show a statistically significant delay…in the overall group or in the Gleason score subgroups," the firm reports. An interim analysis of the secondary measure of overall survival showed similar results to an earlier study, D9901, which demonstrated a survival benefit at three years. Dendreon plans to complete analysis of 9902A in the second half of 2005. The study was halted in 2002 after 98 patients were enrolled and D9901 showed no significant benefit in TTP. Another Phase III study, D9902B, is ongoing...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel